According to the news report the study is already set.
"Study participants will either receive twice daily doses of apabetalone for up to 4 weeks alongside standard of care or, alternatively, standard of care without apabetalone. The primary outcome measure of the study will be change in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement. A total of 100 patients are expected to be enrolled at multiple sites, both in Canada and abroad and enrollment is expected to begin immediately. A full study protocol will be posted to clinicaltrials.gov prior to initiation of the study."
Koo